Comparing VivoSim Labs (NASDAQ:VIVS) & Bruker (NASDAQ:BRKR)

VivoSim Labs (NASDAQ:VIVS) and Bruker (NASDAQ:BRKR) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Volatility & Risk

VivoSim Labs has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Bruker has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for VivoSim Labs and Bruker, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoSim Labs	1	0	0	0	1.00
Bruker	2	5	6	1	2.43

Bruker has a consensus price target of $56.79, suggesting a potential upside of 12.89%. Given Bruker’s stronger consensus rating and higher probable upside, analysts plainly believe Bruker is more favorable than VivoSim Labs.

Valuation and Earnings

This table compares VivoSim Labs and Bruker”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoSim Labs	$131,000.00	9.79	-$13.84 million	($5.36)	-0.07
Bruker	$3.44 billion	2.23	-$8.60 million	($0.24)	-209.58

Bruker has higher revenue and earnings than VivoSim Labs. Bruker is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares VivoSim Labs and Bruker’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VivoSim Labs	-10,567.17%	-277.62%	-153.77%
Bruker	-0.65%	11.60%	4.25%

Insider & Institutional Ownership

8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 79.5% of Bruker shares are held by institutional investors. 2.5% of VivoSim Labs shares are held by insiders. Comparatively, 27.2% of Bruker shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Bruker beats VivoSim Labs on 12 of the 15 factors compared between the two stocks.

About VivoSim Labs

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.